Literature DB >> 26395908

Cytokines in Machado Joseph Disease/Spinocerebellar Ataxia 3.

Gerson da Silva Carvalho1, Jonas Alex Morales Saute1,2, Clarissa Branco Haas3, Vitor Rocco Torrez3, Andressa Wigner Brochier3, Gabriele Nunes Souza1, Gabriel Vasata Furtado3, Tailise Gheno3, Aline Russo1, Thais Lampert Monte1,4, Artur Schumacher-Schuh4, Rui D'Avila2, Karina Carvalho Donis2, Raphael Machado Castilhos3, Diogo Onofre Souza3,5,6, Maria Luiza Saraiva-Pereira3,5,2,7, Vanessa Leotti Torman8,9, Suzi Camey8,9, Luis Valmor Portela3,5,6, Laura Bannach Jardim10,11,12,13,14.   

Abstract

The aim of the present study is to describe the serum concentrations of a broad spectrum of cytokines in symptomatic and asymptomatic carriers of Machado Joseph disease (SCA3/MJD) CAG expansions. Molecularly confirmed carriers and controls were studied. Age at onset, disease duration, and clinical scales Scale for the Assessment and Rating of Ataxia (SARA), Neurological Examination Score for Spinocerebellar Ataxias (NESSCA), SCA Functional Index (SCAFI), and Composite Cerebellar Functional Score (CCFS) were obtained from the symptomatic carriers. Serum was obtained from all individuals and a cytokine panel "consisted of" eotaxin, granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon (IFN)-α, IFN-γ, interleukin (IL)-1β, IL-1RA, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-15, IL-17, interferon gamma-induced protein (IP)-10, monocyte chemoattractant protein (MCP)-1, monokine induced by gamma interferon (MIG), macrophage inflammatory protein (MIP)-a, MIP-b, regulated on activation, normal T cell expressed and secreted (RANTES) and tumor necrosis factor (TNF)-α was analyzed. In a subgroup of symptomatic carriers, the cytokine panel was repeated after 360 days. Cytokine distribution among groups was studied by discriminant analysis; changes in serum levels after 360 days were studied by generalized estimation equation. Sixty-six symptomatic carriers, 13 asymptomatic carriers, and 43 controls were studied. No differences in cytokine patterns were found between controls and carriers of the CAG expansions or between controls and symptomatic carriers only. In contrast, eotaxin concentrations were significantly higher in asymptomatic than in symptomatic carriers or in controls (p = 0.001, ANCOVA). Eotaxin did not correlate with age, disease duration, CAG expansion, NESSCA score, and SARA score. Among symptomatic carriers, eotaxin dropped after 360 days (p = 0.039, GEE). SCA3/MJD patients presented a benign pattern of serum cytokines. In contrast, levels of eotaxin, a peptide secreted by astrocytes, were elevated in the asymptomatic carriers, suggesting that a specific response of these cells can be related to symptom progression, in SCA3/MJD.

Entities:  

Keywords:  Cytokines; Discriminant analysis; Eotaxin; Machado Joseph disease; Neuroprotection; Spinocerebellar ataxia type 3

Mesh:

Substances:

Year:  2016        PMID: 26395908     DOI: 10.1007/s12311-015-0719-z

Source DB:  PubMed          Journal:  Cerebellum        ISSN: 1473-4222            Impact factor:   3.847


  33 in total

1.  Analysis of cytokines and chemokines produced by whole blood, peripheral mononuclear and polymorphonuclear cells.

Authors:  Faas H van Dooren; Nicolette W Duijvis; Anje A te Velde
Journal:  J Immunol Methods       Date:  2013-08-28       Impact factor: 2.303

Review 2.  Physiology of microglia.

Authors:  Helmut Kettenmann; Uwe-Karsten Hanisch; Mami Noda; Alexei Verkhratsky
Journal:  Physiol Rev       Date:  2011-04       Impact factor: 37.312

3.  Presymptomatic testing for neurogenetic diseases in Brazil: assessing who seeks and who follows through with testing.

Authors:  Caroline Santa Maria Rodrigues; Viviane Ziebell de Oliveira; Gabriela Camargo; Claudio Maria da Silva Osório; Raphael Machado de Castilhos; Maria Luiza Saraiva-Pereira; Lavínia Schuler-Faccini; Laura Bannach Jardim
Journal:  J Genet Couns       Date:  2011-06-30       Impact factor: 2.537

4.  Inflammatory genes are upregulated in expanded ataxin-3-expressing cell lines and spinocerebellar ataxia type 3 brains.

Authors:  B O Evert; I R Vogt; C Kindermann; L Ozimek; R A de Vos; E R Brunt; I Schmitt; T Klockgether; U Wüllner
Journal:  J Neurosci       Date:  2001-08-01       Impact factor: 6.167

5.  Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3.

Authors:  Jana Boy; Thorsten Schmidt; Hartwig Wolburg; Andreas Mack; Silke Nuber; Martin Böttcher; Ina Schmitt; Carsten Holzmann; Frank Zimmermann; Antonio Servadio; Olaf Riess
Journal:  Hum Mol Genet       Date:  2009-08-10       Impact factor: 6.150

6.  Motor uncoordination and neuropathology in a transgenic mouse model of Machado-Joseph disease lacking intranuclear inclusions and ataxin-3 cleavage products.

Authors:  Anabela Silva-Fernandes; Maria do Carmo Costa; Sara Duarte-Silva; Pedro Oliveira; Claudia M Botelho; Luís Martins; José António Mariz; Tiago Ferreira; Filipa Ribeiro; Margarida Correia-Neves; Cristina Costa; Patrícia Maciel
Journal:  Neurobiol Dis       Date:  2010-05-25       Impact factor: 5.996

7.  CNS-specific immunity at the choroid plexus shifts toward destructive Th2 inflammation in brain aging.

Authors:  Kuti Baruch; Noga Ron-Harel; Hilah Gal; Aleksandra Deczkowska; Eric Shifrut; Wilfred Ndifon; Nataly Mirlas-Neisberg; Michal Cardon; Ilan Vaknin; Liora Cahalon; Tamara Berkutzki; Mark P Mattson; Fernando Gomez-Pinilla; Nir Friedman; Michal Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-18       Impact factor: 11.205

8.  Spinocerebellar ataxias in Brazil--frequencies and modulating effects of related genes.

Authors:  Raphael Machado de Castilhos; Gabriel Vasata Furtado; Tailise Conte Gheno; Paola Schaeffer; Aline Russo; Orlando Barsottini; José Luiz Pedroso; Diego Z Salarini; Fernando Regla Vargas; Maria Angélica de Faria Domingues de Lima; Clécio Godeiro; Luiz Carlos Santana-da-Silva; Maria Betânia Pereira Toralles; Silvana Santos; Hélio van der Linden; Hector Yuri Wanderley; Paula Frassineti Vanconcelos de Medeiros; Eliana Ternes Pereira; Erlane Ribeiro; Maria Luiza Saraiva-Pereira; Laura Bannach Jardim
Journal:  Cerebellum       Date:  2014-02       Impact factor: 3.847

Review 9.  Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain.

Authors:  Geeta Ramesh; Andrew G MacLean; Mario T Philipp
Journal:  Mediators Inflamm       Date:  2013-08-12       Impact factor: 4.711

Review 10.  Interleukin-6, a major cytokine in the central nervous system.

Authors:  María Erta; Albert Quintana; Juan Hidalgo
Journal:  Int J Biol Sci       Date:  2012-10-25       Impact factor: 6.580

View more
  15 in total

1.  Promoter Variation and Expression Levels of Inflammatory Genes IL1A, IL1B, IL6 and TNF in Blood of Spinocerebellar Ataxia Type 3 (SCA3) Patients.

Authors:  Mafalda Raposo; Conceição Bettencourt; Amanda Ramos; Nadiya Kazachkova; João Vasconcelos; Teresa Kay; Jácome Bruges-Armas; Manuela Lima
Journal:  Neuromolecular Med       Date:  2016-05-31       Impact factor: 3.843

Review 2.  Spinocerebellar ataxias: prospects and challenges for therapy development.

Authors:  Tetsuo Ashizawa; Gülin Öz; Henry L Paulson
Journal:  Nat Rev Neurol       Date:  2018-10       Impact factor: 42.937

Review 3.  Founder Effects of Spinocerebellar Ataxias in the American Continents and the Caribbean.

Authors:  Roberto Rodríguez-Labrada; Ana Carolina Martins; Jonathan J Magaña; Yaimeé Vazquez-Mojena; Jacqueline Medrano-Montero; Juan Fernandez-Ruíz; Bulmaro Cisneros; Helio Teive; Karen N McFarland; Maria Luiza Saraiva-Pereira; César M Cerecedo-Zapata; Christopher M Gomez; Tetsuo Ashizawa; Luis Velázquez-Pérez; Laura Bannach Jardim
Journal:  Cerebellum       Date:  2020-06       Impact factor: 3.847

Review 4.  Rating scales and biomarkers for CAG-repeat spinocerebellar ataxias: Implications for therapy development.

Authors:  Meng-Ling Chen; Chih-Chun Lin; Liana S Rosenthal; Puneet Opal; Sheng-Han Kuo
Journal:  J Neurol Sci       Date:  2021-04-01       Impact factor: 3.181

Review 5.  Spinocerebellar ataxia clinical trials: opportunities and challenges.

Authors:  Sarah M Brooker; Chandrakanth Reddy Edamakanti; Sara M Akasha; Sheng-Han Kuo; Puneet Opal
Journal:  Ann Clin Transl Neurol       Date:  2021-05-21       Impact factor: 4.511

6.  Neuromyelitis Optica Spectrum Disorder Coinciding with Spinocerebellar Ataxia Type 31.

Authors:  Yoshiaki Takahashi; Yasuhiro Manabe; Ryuta Morihara; Hisashi Narai; Toru Yamashita; Koji Abe
Journal:  Case Rep Neurol       Date:  2017-05-17

Review 7.  Identifying Therapeutic Targets for Spinocerebellar Ataxia Type 3/Machado-Joseph Disease through Integration of Pathological Biomarkers and Therapeutic Strategies.

Authors:  Yu-Shuan Chen; Zhen-Xiang Hong; Shinn-Zong Lin; Horng-Jyh Harn
Journal:  Int J Mol Sci       Date:  2020-04-26       Impact factor: 5.923

Review 8.  Recent advances in understanding dominant spinocerebellar ataxias from clinical and genetic points of view.

Authors:  Giulia Coarelli; Alexis Brice; Alexandra Durr
Journal:  F1000Res       Date:  2018-11-12

9.  Serum neurofilament light chain as a severity marker for spinocerebellar ataxia.

Authors:  Hye-Rim Shin; Jangsup Moon; Woo-Jin Lee; Han Sang Lee; Eun Young Kim; Seoyi Shin; Soon-Tae Lee; Keun-Hwa Jung; Kyung-Il Park; Ki-Young Jung; Sang Kun Lee; Kon Chu
Journal:  Sci Rep       Date:  2021-06-29       Impact factor: 4.379

10.  Peripheral Oxidative Stress Biomarkers in Spinocerebellar Ataxia Type 3/Machado-Joseph Disease.

Authors:  Adriano M de Assis; Jonas Alex Morales Saute; Aline Longoni; Clarissa Branco Haas; Vitor Rocco Torrez; Andressa Wigner Brochier; Gabriele Nunes Souza; Gabriel Vasata Furtado; Tailise Conte Gheno; Aline Russo; Thais Lampert Monte; Raphael Machado Castilhos; Artur Schumacher-Schuh; Rui D'Avila; Karina Carvalho Donis; Carlos Roberto de Mello Rieder; Diogo Onofre Souza; Suzi Camey; Vanessa Bielefeldt Leotti; Laura Bannach Jardim; Luis Valmor Portela
Journal:  Front Neurol       Date:  2017-09-20       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.